Nice_老虎社区_美港股上老虎

Miracle99
2021-09-10

Nice

Moderna working on combination COVID-19 vaccine booster and flu shot

Moderna Inc said on Thursday it is developing a single vaccine that combines a booster dose against

Moderna working on combination COVID-19 vaccine booster and flu shot

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":883855089,"tweetId":"883855089","gmtCreate":1631234342341,"gmtModify":1631885838997,"author":{"id":3581573678394869,"idStr":"3581573678394869","authorId":3581573678394869,"authorIdStr":"3581573678394869","name":"Miracle99","avatar":"https://static.tigerbbs.com/1cfacd38670cd13d8111d4ffe2d88a3f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/883855089","repostId":2166347939,"repostType":4,"repost":{"id":"2166347939","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631233777,"share":"https://www.laohu8.com/m/news/2166347939?lang=&edition=full","pubTime":"2021-09-10 08:29","market":"us","language":"en","title":"Moderna working on combination COVID-19 vaccine booster and flu shot","url":"https://stock-news.laohu8.com/highlight/detail?id=2166347939","media":"Reuters","summary":"Moderna Inc said on Thursday it is developing a single vaccine that combines a booster dose against ","content":"<p>Moderna Inc said on Thursday it is developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot.</p>\n<p>The company hopes to eventually add vaccines it is working on for respiratory syncytial virus (RSV) and other respiratory diseases as an annual shot.</p>\n<p>\"We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster,\" Moderna Chief Executive Officer Stéphane Bancel said during a presentation to update investors on its drugs in development.</p>\n<p>\"We believe Moderna could be first to market in this important new opportunity,\" he said.</p>\n<p>The company is conducting clinical trials for an RSV vaccine in older adults.</p>\n<p>Moderna and Pfizer Inc&nbsp;and German vaccine partner BioNTech SE are already&nbsp;expected to reap billions&nbsp;of dollars from COVID-19 booster shots, analysts and healthcare investors said. Adding influenza and other diseases could further boost those profits.</p>\n<p>Moderna shares rose 7.8% on Thursday.</p>\n<p>The drugmaker already had several influenza vaccine candidates in development. The new vaccine combines the experimental flu shot that is furthest along with its COVID-19 vaccine.</p>\n<p>Oppenheimer &amp; Co analyst Hartaj Singh said the news that clinical testing of combination vaccines was likely to begin over the next 6-12 months was a positive surprise for investors.</p>\n<p>\"The question becomes that after the pandemic is over, how much do total vaccine sales become and how much can Moderna expand that market,\" Singh said.</p>\n<p>Novavax Inc, which does not yet have U.S. authorization for its COVID-19 vaccine, said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 shots.</p>\n<p>Moderna also provided updates on its ongoing mid-stage trial testing its authorized COVID-19 vaccine in children aged 6 months to 11 years old. It is testing a 50-microgram dose of the shot in the pediatric trial involving 4,000 children.</p>\n<p>Moderna's vaccine, which received an emergency use authorization for two 100-microgram doses for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.</p>\n<p>Moderna said dose selection studies for different age groups such as 2 years to less than 6 years, and 6 months to below 2 years old, were still underway.</p>\n<p>The Pfizer/BioNTech vaccine was authorized for those aged 12 to 15 earlier this year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna working on combination COVID-19 vaccine booster and flu shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna working on combination COVID-19 vaccine booster and flu shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-10 08:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna Inc said on Thursday it is developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot.</p>\n<p>The company hopes to eventually add vaccines it is working on for respiratory syncytial virus (RSV) and other respiratory diseases as an annual shot.</p>\n<p>\"We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster,\" Moderna Chief Executive Officer Stéphane Bancel said during a presentation to update investors on its drugs in development.</p>\n<p>\"We believe Moderna could be first to market in this important new opportunity,\" he said.</p>\n<p>The company is conducting clinical trials for an RSV vaccine in older adults.</p>\n<p>Moderna and Pfizer Inc&nbsp;and German vaccine partner BioNTech SE are already&nbsp;expected to reap billions&nbsp;of dollars from COVID-19 booster shots, analysts and healthcare investors said. Adding influenza and other diseases could further boost those profits.</p>\n<p>Moderna shares rose 7.8% on Thursday.</p>\n<p>The drugmaker already had several influenza vaccine candidates in development. The new vaccine combines the experimental flu shot that is furthest along with its COVID-19 vaccine.</p>\n<p>Oppenheimer &amp; Co analyst Hartaj Singh said the news that clinical testing of combination vaccines was likely to begin over the next 6-12 months was a positive surprise for investors.</p>\n<p>\"The question becomes that after the pandemic is over, how much do total vaccine sales become and how much can Moderna expand that market,\" Singh said.</p>\n<p>Novavax Inc, which does not yet have U.S. authorization for its COVID-19 vaccine, said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 shots.</p>\n<p>Moderna also provided updates on its ongoing mid-stage trial testing its authorized COVID-19 vaccine in children aged 6 months to 11 years old. It is testing a 50-microgram dose of the shot in the pediatric trial involving 4,000 children.</p>\n<p>Moderna's vaccine, which received an emergency use authorization for two 100-microgram doses for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.</p>\n<p>Moderna said dose selection studies for different age groups such as 2 years to less than 6 years, and 6 months to below 2 years old, were still underway.</p>\n<p>The Pfizer/BioNTech vaccine was authorized for those aged 12 to 15 earlier this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166347939","content_text":"Moderna Inc said on Thursday it is developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot.\nThe company hopes to eventually add vaccines it is working on for respiratory syncytial virus (RSV) and other respiratory diseases as an annual shot.\n\"We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster,\" Moderna Chief Executive Officer Stéphane Bancel said during a presentation to update investors on its drugs in development.\n\"We believe Moderna could be first to market in this important new opportunity,\" he said.\nThe company is conducting clinical trials for an RSV vaccine in older adults.\nModerna and Pfizer Inc and German vaccine partner BioNTech SE are already expected to reap billions of dollars from COVID-19 booster shots, analysts and healthcare investors said. Adding influenza and other diseases could further boost those profits.\nModerna shares rose 7.8% on Thursday.\nThe drugmaker already had several influenza vaccine candidates in development. The new vaccine combines the experimental flu shot that is furthest along with its COVID-19 vaccine.\nOppenheimer & Co analyst Hartaj Singh said the news that clinical testing of combination vaccines was likely to begin over the next 6-12 months was a positive surprise for investors.\n\"The question becomes that after the pandemic is over, how much do total vaccine sales become and how much can Moderna expand that market,\" Singh said.\nNovavax Inc, which does not yet have U.S. authorization for its COVID-19 vaccine, said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 shots.\nModerna also provided updates on its ongoing mid-stage trial testing its authorized COVID-19 vaccine in children aged 6 months to 11 years old. It is testing a 50-microgram dose of the shot in the pediatric trial involving 4,000 children.\nModerna's vaccine, which received an emergency use authorization for two 100-microgram doses for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.\nModerna said dose selection studies for different age groups such as 2 years to less than 6 years, and 6 months to below 2 years old, were still underway.\nThe Pfizer/BioNTech vaccine was authorized for those aged 12 to 15 earlier this year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":253,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

Moderna working on combination COVID-19 vaccine booster and flu shot

评论（1）

热议股票